Gilenya is Novartis' third-biggest product and the top seller in its neuroscience franchise, bringing in revenues of almost $2.8 billion in 2021, although sales have started to decline due to ...

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on ...

It will not be the most expensive but it will not be the cheapest – a very effective drug at the same list price as Gilenya.” When NICE assessed Gilenya back in 2012, it said the drug costs ...

Optum Rx has eliminated prior authorization for almost 70 drugs for chronic diseases, about 10% of its overall pharmacy prior ...

Medicare covers many treatments for multiple sclerosis (MS) under different parts of Medicare. However, it does not cover experimental treatments. If you or a loved one has MS and are eligible for ...